Radiation Safety and External Radiation Exposure Rate of Patients Receiving I-131 Therapy for Hyperthyroidism and Remnant Ablation as Outpatient: An Institutional Experience

Abstract

Objective Our objective was to study the radiation exposure rate as function of time in the administration of radioiodine iodine-131 (I-131) for the treatment of thyrotoxicosis or Graves' disease and remnant ablation on an outpatient basis at the Department of Nuclear Medicine, and also, to study the impact of revised discharge criteria for radioiodine therapy enforced by the Atomic Energy Regulatory Board (AERB) of India.

Materials and Methods This study included patients who underwent low-dose radioiodine therapy using I-131. Patients were classified into two different groups, that is, group A and group B. Group A included patients receiving low dose I-131 for the treatment of thyrotoxicosis, whereas group B included patients receiving I-131 therapy for the ablation of residual thyroid tissue after total thyroidectomy. The radiation exposure rate was measured using a radiation detector in milli roentgen per hour (mR/h) at 5 cm distance of stomach and neck levels and with the patient standing at the distance of 1 m after oral administration of I-131 at 0, 1, and 2 hours.

Results A total of 134 (17 males and 117 females) patients were included in the study. Group A comprised 102 (14 male and 88 females) patients and group B of 32 (3 males and 29 females) patients. At the neck level, the average exposure rate in group A versus group B after 0, 1, and 2 hours was observed to be 6.9 versus 22.27 mR/h, 33.67 versus 43.39 mR/h, and 41.75 versus 48.90 mR/h, respectively. At the stomach level, the exposure rate was 23.65 versus 71.32 mR/h, 13.27 versus 48.45 mR/h, and 9.91 versus 39.43 mR/h after 0, 1, and 2 hours, respectively. At a distance of 1 m, the exposure rate was 1.31 versus 2.99 mR/h, 1.05 versus 2.58 mR/h, and 0.92 versus 2.21 mR/h, respectively.

Conclusion Exposure rate measured for patients treated with up to 1,110 MBq (30 mCi) of I-131 was under permissible limits as per revised discharged limits, that is, 50 µSv/h (5 mR/h) prescribed by AERB, India. The patients undergoing radioiodine therapy I-131 (up to 1,110 MBq/30 mCi) can be discharged safely 2 hours postadministration following good work practice along with providing proper radiation safety instructions to patients.

Keywords

radioiodine therapy - thyrotoxicosis - ablation - outpatient - radiation exposure

Authors' Contribution

N.B. was responsible for conception and design of study, generation of data, interpretation of data, drafting the manuscript, providing critical intellectual input, and approval of final version to be published. V.K.D. was responsible for drafting the manuscript, providing critical intellectual input, and approval of final version to be published. P.M. was responsible for drafting the manuscript, providing critical intellectual input, and approval of final version to be published. S.S. was responsible for drafting the manuscript, providing critical intellectual input, and approval of final version to be published. The work is original and not submitted or published in any other journal. This manuscript has been read and approved by all the authors. All authors have contributed significantly and are in agreement with the content of the manuscript and take responsibility for it.

Publication History

Article published online:
06 September 2023

• References

• 1 Mumtaz M, Lin LS, Hui KC, Mohd Khir AS. Radioiodine I-131 for the therapy of graves' disease. Malays J Med Sci 2009; 16 (01) 25-33
• 2 Shinto AS, Pachen L, Sreekanth TK. Fixed dose radioactive iodine therapy in hyperthyroidism: outcome and factors affecting it in a region in South India. Thyroid Science. 2010; 5 (06) 1-7
• 3 Zhang H, Jiao L, Cui S. et al. The study of external dose rate and retained body activity of patients receiving 131I therapy for differentiated thyroid carcinoma. Int J Environ Res Public Health 2014; 11 (10) 10991-11003
• 4 Yeong CH, Cheng MH, Ng KH. Therapeutic radionuclides in nuclear medicine: current and future prospects. J Zhejiang Univ Sci B 2014; 15 (10) 845-863
• 5 Barrington SF, Kettle AG, O'Doherty MJ, Wells CP, Somer EJ, Coakley AJ. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. Eur J Nucl Med 1996; 23 (02) 123-130
• 6 Tanton P. Radiation safety in nuclear imaging and radionuclide therapy. Indian J Nucl Med 2007; 22: 122
• 7 Atomic Energy Regulatory Board. AERB Safety Code for Nuclear Medicine Facilities. . AERB Safety Code No. AERB/RF-MED/SC-2 (Rev. 2), 2011 . Accessed on July 14, 2023, at: http://www.aerb.gov.in/AERBPortal/pages/English/t/publications/CODESGUIDES/NM_Code.pdf
• 8 Ravichandran R, Binukumar J, Saadi AA. Estimation of effective half life of clearance of radioactive iodine (I) in patients treated for hyperthyroidism and carcinoma thyroid. Indian J Nucl Med 2010; 25 (02) 49-52
• 9 International Atomic Energy Agency (IAEA). . Applying Radiation Safety Standards in Nuclear Medicine, Safety Reports Series No. 40. Vienna: IAEA; 2005. Accessed on July 14, 2023, at: https://www.iaea.org/publications/7116/applying-radiation-safety-standards-in-nuclear-medicine#:~:text=INTERNATIONAL%20ATOMIC%20ENERGY%20AGENCY%2C%20Applying%20Radiation%20Safety%20Standards%20in%20Nuclear%20Medicine%2C%20Safety%20Reports%20Series%20No.%2040%2C%20IAEA%2C%20Vienna%20(2005)
• 10 International Atomic Energy Agency (IAEA). Release of Patients After Radionuclide Therapy, Safety Reports Series No. 63. Vienna: IAEA; 2009. Accessed on July 14, 2023, at: https://www.iaea.org/publications/8179/release-of-patients-after-radionuclide-therapy#:~:text=INTERNATIONAL%20ATOMIC%20ENERGY%20AGENCY%2C%20Release%20of%20Patients%20After%20Radionuclide%20Therapy%2C%20Safety%20Reports%20Series%20No.%2063%2C%20IAEA%2C%20Vienna%20(2009)
• 11 Hänscheid H, Lassmann M, Luster M. et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006; 47 (04) 648-654
• 12 Sisson JC, Freitas J, McDougall IR. et al; American Thyroid Association Taskforce On Radioiodine Safety. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association. Thyroid 2011; 21 (04) 335-346